Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. Postal Service Health Care Proposal Would Shift 480,000 Retirees Into Part D

This article was originally published in The Pink Sheet Daily

Executive Summary

The proposal to shift retirees into Medicare Part D is part of a broader plan to reduce health care costs at the struggling organization. It would also require all USPS retirees to enroll in Medicare Parts A and B.

You may also be interested in...



Manufacturers’ Drug Discount Obligation Won’t Be Reduced In Part D Retiree Plans Under CMS Policy

A new Medicare Part D policy on calculating the 50% discount on branded drugs in the coverage gap will not allow for reduced manufacturer payments when beneficiaries are enrolled in employer group waiver plans, despite arguments from drug firms.

Lilly’s ‘High Quality’ Donanemab Data Supports Unrestricted Medicare Coverage, Firm Says

As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.

340B Audit ‘Protections’ Needed Prior To Dispute Resolution Final Rule, Lilly Tells OMB

Lilly wants White House Office of Management and Budget to delay final rule until there are regulatory controls against duplicate and diverted discounts. OMB has also held three meetings over past few months with organizations representing 340B providers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel